Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status

• DOI: 10.1097/cad.0b013e3283493160
• Publication Date: 2011-07-27T09:04:00Z
• Authors: Dominik P. Modest; Sebastian Stintzing; Ruediger P. Laube...; Jens Neumann; Andreas Jung; Clemens Giessen; Michael Haas; Philipp Aubele; Christoph Schulz; Stefan Boeck; Hans-Joachim Stem...; Thomas Kirchner; Volker Heinemann
• Keywords: FOLFIRI

This retrospective study investigated the clinical characteristics of patients with metastatic colorectal cancer (mCRC) depending on KRAS status, thereby differentiating exon 2 mutations in codon 12 versus 13. In total, 273 mCRC receiving first-line therapy were analyzed. One hundred treated within FIRE-3 trial (FOLFIRI plus cetuximab or bevacizumab), 147 AIO KRK-0104 (cetuximab CAPIRI CAPOX), and further 26 received outside study. Thirty-eight tumors mutation 13, 140 12, 95 wild type as a comparison included this analysis. Bivariate analyses demonstrated significant differences between wild-type, 12-mutated, 13-mutated regard to synchronous lymph node metastasis (P=0.018), organ (76.8% vs. 65.9% 89.5%, P=0.009), liver (89.5% 78.2% 92.1%, P=0.025), lung (29.5% 42.9% 50%, P=0.041), liver-only (48.4% 28.8% 28.9%, P=0.006), metastases two more organs (49.5, 61.4, 71.1, P=0.047). Regression models indicated impact 13 for nodal (P=0.01, 0.03). pooled analysis indicates that is heterogeneous disease, which seems be defined by tumor. Compared mutations, presents aggressive disease frequently associated local distant at first diagnosis.